CLIA deadline extension
This article was originally published in The Gray Sheet
Executive Summary
Health Care Financing Administration is aiming to publish in the next few weeks a notice in the Federal Register extending the Sept. 1, 1994 deadline by which all in vitro diagnostic test labeling was supposed to conform to the quality control provisions of the Clinical Laboratories Improvement Amendments of 1988 ("The Gray Sheet" Jan. 10, I&W-6). An extension of two to four years is expected. Under current regs, laboratories can not after Sept. 1 use IVD QC instructions as a substitute for CLIA QC rules unless the labeling is cleared by FDA. HCFA says it will not enforce the provision if the extension is not published before the deadline
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.